FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3091858153> ?p ?o ?g. }

• W3091858153 endingPage "470" @default.
• W3091858153 startingPage "457" @default.
• W3091858153 abstract "The potential of members of the epidermal growth factor receptor (ErbB) family as drug targets in cholangiocarcinoma (CCA) has not been extensively addressed. Although phase III clinical trials showed no survival benefits of erlotinib in patients with advanced CCA, the outcome of the standard-of-care chemotherapy treatment for CCA, gemcitabine/cisplatin, is discouraging so we determined the effect of other ErbB receptor inhibitors alone or in conjunction with chemotherapy in CCA cells.ErbB receptor expression was determined in CCA patient tissues by immunohistochemistry and digital-droplet polymerase chain reaction, and in primary cells and cell lines by immunoblot. Effects on cell viability and cell cycle distribution of combination therapy using ErbB inhibitors with chemotherapeutic drugs was carried out in CCA cell lines. 3D culture of primary CCA cells was then adopted to evaluate the drug effect in a setting that more closely resembles in vivo cell environments.CCA tumors showed higher expression of all ErbB receptors compared with resection margins. Primary and CCA cell lines had variable expression of erbB receptors. CCA cell lines showed decreased cell viability when treated with chemotherapeutic drugs (gemcitabine and 5-fluorouracil) but also with ErbB inhibitors, particularly afatinib, and with a combination. Sequential treatment of gemcitabine with afatinib was particularly effective. Co-culture of CCA primary cells with cancer-associated fibroblasts decreased sensitivity to chemotherapies, but sensitized to afatinib.Afatinib is a potential epidermal growth factor receptor targeted drug for CCA treatment and sequential treatment schedule of gemcitabine and afatinib could be explored in CCA patients." @default.
• W3091858153 created "2020-10-15" @default.
• W3091858153 creator A5000418234 @default.
• W3091858153 creator A5007481005 @default.
• W3091858153 creator A5015078382 @default.
• W3091858153 creator A5023058464 @default.
• W3091858153 creator A5031840950 @default.
• W3091858153 creator A5033723598 @default.
• W3091858153 creator A5035672691 @default.
• W3091858153 creator A5038774003 @default.
• W3091858153 creator A5039813640 @default.
• W3091858153 creator A5040089156 @default.
• W3091858153 creator A5041136453 @default.
• W3091858153 creator A5045154271 @default.
• W3091858153 creator A5050298357 @default.
• W3091858153 creator A5051258492 @default.
• W3091858153 creator A5060719050 @default.
• W3091858153 creator A5062676672 @default.
• W3091858153 creator A5063267862 @default.
• W3091858153 creator A5071024866 @default.
• W3091858153 creator A5071183440 @default.
• W3091858153 creator A5075804962 @default.
• W3091858153 creator A5085153634 @default.
• W3091858153 date "2021-04-15" @default.
• W3091858153 modified "2023-10-16" @default.
• W3091858153 title "Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells" @default.
• W3091858153 cites W1542825229 @default.
• W3091858153 cites W1974253337 @default.
• W3091858153 cites W1983134337 @default.
• W3091858153 cites W1998914462 @default.
• W3091858153 cites W2000577272 @default.
• W3091858153 cites W2006970521 @default.
• W3091858153 cites W2008631520 @default.
• W3091858153 cites W2012369608 @default.
• W3091858153 cites W2012915718 @default.
• W3091858153 cites W2015918488 @default.
• W3091858153 cites W2034975420 @default.
• W3091858153 cites W2035220546 @default.
• W3091858153 cites W2062109911 @default.
• W3091858153 cites W2062138514 @default.
• W3091858153 cites W2081114497 @default.
• W3091858153 cites W2096439168 @default.
• W3091858153 cites W2134964659 @default.
• W3091858153 cites W2138604360 @default.
• W3091858153 cites W2143536404 @default.
• W3091858153 cites W2164864298 @default.
• W3091858153 cites W2289550863 @default.
• W3091858153 cites W231374523 @default.
• W3091858153 cites W2529047469 @default.
• W3091858153 cites W2534288116 @default.
• W3091858153 cites W2552699553 @default.
• W3091858153 cites W2559761169 @default.
• W3091858153 cites W2564810646 @default.
• W3091858153 cites W2587138214 @default.
• W3091858153 cites W2729725748 @default.
• W3091858153 cites W2808643725 @default.
• W3091858153 cites W2895049718 @default.
• W3091858153 cites W2920758868 @default.
• W3091858153 cites W2996098638 @default.
• W3091858153 doi "https://doi.org/10.4143/crt.2020.585" @default.
• W3091858153 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8053863" @default.
• W3091858153 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33070556" @default.
• W3091858153 hasPublicationYear "2021" @default.
• W3091858153 type Work @default.
• W3091858153 sameAs 3091858153 @default.
• W3091858153 citedByCount "7" @default.
• W3091858153 countsByYear W30918581532021 @default.
• W3091858153 countsByYear W30918581532022 @default.
• W3091858153 countsByYear W30918581532023 @default.
• W3091858153 crossrefType "journal-article" @default.
• W3091858153 hasAuthorship W3091858153A5000418234 @default.
• W3091858153 hasAuthorship W3091858153A5007481005 @default.
• W3091858153 hasAuthorship W3091858153A5015078382 @default.
• W3091858153 hasAuthorship W3091858153A5023058464 @default.
• W3091858153 hasAuthorship W3091858153A5031840950 @default.
• W3091858153 hasAuthorship W3091858153A5033723598 @default.
• W3091858153 hasAuthorship W3091858153A5035672691 @default.
• W3091858153 hasAuthorship W3091858153A5038774003 @default.
• W3091858153 hasAuthorship W3091858153A5039813640 @default.
• W3091858153 hasAuthorship W3091858153A5040089156 @default.
• W3091858153 hasAuthorship W3091858153A5041136453 @default.
• W3091858153 hasAuthorship W3091858153A5045154271 @default.
• W3091858153 hasAuthorship W3091858153A5050298357 @default.
• W3091858153 hasAuthorship W3091858153A5051258492 @default.
• W3091858153 hasAuthorship W3091858153A5060719050 @default.
• W3091858153 hasAuthorship W3091858153A5062676672 @default.
• W3091858153 hasAuthorship W3091858153A5063267862 @default.
• W3091858153 hasAuthorship W3091858153A5071024866 @default.
• W3091858153 hasAuthorship W3091858153A5071183440 @default.
• W3091858153 hasAuthorship W3091858153A5075804962 @default.
• W3091858153 hasAuthorship W3091858153A5085153634 @default.
• W3091858153 hasBestOaLocation W30918581531 @default.
• W3091858153 hasConcept C121608353 @default.
• W3091858153 hasConcept C126322002 @default.
• W3091858153 hasConcept C143998085 @default.
• W3091858153 hasConcept C170493617 @default.
• W3091858153 hasConcept C2777506169 @default.
• W3091858153 hasConcept C2778087573 @default.

• next